Rina G Das

US Patent:

7175981, Feb 13, 2007

Filed:

Nov 30, 1999

Appl. No.:

09/451513

Inventors:

Marti Jett - Washington DC, US
Rina Das - Rockville MD, US
Roger Neill - Rockville MD, US

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

C12Q 1/68
G01N 33/53
G01N 33/567
G01N 33/48

US Classification:

435 6, 435 71, 435 72, 435 721, 435 723, 436 63, 436 64

Abstract:

A method of diagnosing the stage or aggressiveness of cancer and particularly breast and prostate cancer by measuring the deviation of levels of fatty acid binding proteins in mammalian tissue or body fluids from normal levels of fatty acid binding proteins. The invention relates to a family of key proteins called fatty acid binding proteins which are involved in metabolism of AA and other lipids and how they affect the proliferation of cancer cells.

US Patent:

20030044790, Mar 6, 2003

Filed:

Jun 7, 2001

Appl. No.:

09/876249

Inventors:

Rina Das - Rockville MD, US
Marti Jett - Washington DC, US
Chanaka Mendis - Falls Church VA, US

International Classification:

C12Q001/68
G01N033/554
G01N033/569

US Classification:

435/006000, 435/007320

Abstract:

A method of diagnosing exposure to a toxic agent comprising the steps of detecting the amount of protein/gene expression present in a sample of mammalian tissue or mammalian body fluids that has not been exposed to a toxic agent. Then the amount of protein/gene expression present in a sample of mammalian tissue or mammalian body fluids that has been exposed to the toxic agent is detected. A determination of the difference in the detected amount of protein/gene expression between the exposed and unexposed samples is made. A comparison of the difference to a library of expected protein/gene expression for predetermined toxic agents is made. Finally, an evaluation is made whether the difference indicates the exposure to a particular toxic agent. A treatment method for administering a therapeutic agent which inhibits the mechanistic pathways necessary to maintain the progression of lethal shock is also disclosed.

US Patent:

20050272055, Dec 8, 2005

Filed:

Dec 1, 2004

Appl. No.:

11/000615

Inventors:

Rina Das - Rockville MD, US
Marti Jett - Washington DC, US
Chanaka Mendis - Platteville WI, US
Roger Neill - Rockville MD, US

International Classification:

C12Q001/68
A61K031/55

US Classification:

435006000

Abstract:

A method for administering a therapeutic agent which inhibits the mechanistic pathways necessary to maintain the progression of lethal shock. The therapeutic agent is administered in the form of a drug, antisense or protein depending on the gene expression.

US Patent:

63161974, Nov 13, 2001

Filed:

Feb 1, 2000

Appl. No.:

9/495724

Inventors:

Rina Das - Rockville MD
Marti Jett - Washington DC
Chanaka Mendis - Falls Church VA

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

C12Q 168
C12P 1934
C07H 2104

US Classification:

435 6

Abstract:

A method of diagnosing exposure to a toxic agent comprising the steps of detecting the amount of protein/gene expression present in a sample of mammalian tissue or mammalian body fluids that has not been exposed to a toxic agent. Then the amount of protein/gene expression present in a sample of mammalian tissue or mammalian body fluids that has been exposed to the toxic agent is detected. A determination of the difference in the detected amount of protein/gene expression between the exposed and unexposed samples is made. A comparison of the difference to a library of expected protein/gene expression for predetermined toxic agents is made. Finally, an evaluation is made whether the difference indicates the exposure to a particular toxic agent. A treatment method for administering a therapeutic agent which inhibits the mechanistic pathways necessary to maintain the progression of lethal shock is also disclosed.